Top Markets
Coin of the day
Mabwell (Shanghai) Bioscience Co., Ltd. Mabwell (Shanghai) Bioscience Co., Ltd.

Mabwell (Shanghai) Bioscience Co., Ltd.

688062
Rank in Stocks #7097
Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience... Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.
Share Price
$4.31
Market Cap
$1.72B
Change (1 day)
0.10%
Change (1 year)
-32.78%
Country
CN
Trade Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Category

Stock price history for Mabwell (Shanghai) Bioscience Co., Ltd. (688062)
Highest end of day price: $4.60 on 2026-08-01

Lowest end of day price: $3.88 on 2022-01-01
Stock price history of Mabwell (Shanghai) Bioscience Co., Ltd. from 2022 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) -4.93%
2025 84.63%
2024 -29.85%
2023 101.02%
2022 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.21 -12.72%
AU
$140.81 475.44%
US
$765.25 7.74%
CH